Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer

Rebecca C. Arend, MD
Published: Friday, Jul 07, 2017



Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.

This trial included patients with high/intermediate risk who received either radiation or radiation plus chemotherapy. According to Arend, if a patient has stage 3 endometrial cancer they should receive chemotherapy.
 
SELECTED
LANGUAGE


Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.

This trial included patients with high/intermediate risk who received either radiation or radiation plus chemotherapy. According to Arend, if a patient has stage 3 endometrial cancer they should receive chemotherapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x